

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
18 June 2020 (18.06.2020)



(10) International Publication Number
WO 2020/120463 A1

(51) International Patent Classification:

A61K 47/54 (2017.01) C07K 14/62 (2006.01)

A61P 5/50 (2006.01) A61K 38/00 (2006.01)

(21) International Application Number:

PCT/EP2019/084400

(22) International Filing Date:

10 December 2019 (10.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18306659.6 11 December 2018 (11.12.2018) EP

18306658.8 11 December 2018 (11.12.2018) EP

18306657.0 11 December 2018 (11.12.2018) EP

(71) Applicant: **SANOFI** [FR/FR]; 54, rue La Boétie, 75008 Paris (FR).

(72) Inventors: **MENDEZ PEREZ, Maria**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **RACKELMANN, Nils**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **BIALY, Laurent**; Bayer SAS, Bayer CropScience France, Crop Science Disease Control, 14, impasse Pierre Baizet CS 99163, 69263 Lyon (FR). **GUESSREGEN, Stefan**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **WILL, Martin**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **BOEHME, Thomas**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **VILLAR GAREIA, Ana**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **KORN, Marcus Hermann**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **BESENIUS, Melissa**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **RIEDEL, Jens**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **WERNER, Ulrich**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).

(74) Agent: **ALTMANN STÖSSEL DICK PATENTANWÄLTE PARTG MBB**; Dudenstraße 46, 68167 Mannheim (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: INSULIN CONJUGATES

(57) Abstract: The present invention relates to a conjugate comprising a sulfonamide of formula (I) and an active pharmaceutical ingredient such as an insulin analog comprising at least one mutation relative to the parent insulin, wherein the insulin analog comprises a mutation at position B16 which is substituted with a hydrophobic amino acid and/or a mutation at position B25 which is substituted with a hydrophobic amino acid. The present invention further relates to a sulfonamide of formula (A). Moreover, the present invention relates to an insulin analog comprising at least one mutation relative to the parent insulin.

WO 2020/120463 A1